1.北京中医药大学东直门医院,北京市东城区海运仓5号, 100700
2.国家儿童医学中心/首都医科大学附属北京儿童医院
bch_hq@126.com
收稿:2023-02-23,
修回:2023-04-30,
纸质出版:2023-06-17
移动端阅览
林筱萱,何强,张晓辉等.通络利胆汤治疗低γ-谷氨酰转肽酶型婴儿胆汁淤积性肝病肝络瘀滞、湿热内蕴证72例临床观察[J].中医杂志,2023,64(12):1248-1254.
LIN Xiaoxuan,HE Qiang,ZHANG Xiaohui,et al.Treatment of Low γ-Glutamyl Transpeptidase Type of Infantile Cholestatic Liver Disease with Liver Colla-terals Obstruction and Damp-heat Internal Accumulation Syndrome by Tongluo Lidan Decoction (通络利胆汤):72 Cases Clinical Observation[J].Journal of Traditional Chinese Medicine,2023,64(12):1248-1254.
林筱萱,何强,张晓辉等.通络利胆汤治疗低γ-谷氨酰转肽酶型婴儿胆汁淤积性肝病肝络瘀滞、湿热内蕴证72例临床观察[J].中医杂志,2023,64(12):1248-1254. DOI: 10.13288/j.11-2166/r.2023.12.011.
LIN Xiaoxuan,HE Qiang,ZHANG Xiaohui,et al.Treatment of Low γ-Glutamyl Transpeptidase Type of Infantile Cholestatic Liver Disease with Liver Colla-terals Obstruction and Damp-heat Internal Accumulation Syndrome by Tongluo Lidan Decoction (通络利胆汤):72 Cases Clinical Observation[J].Journal of Traditional Chinese Medicine,2023,64(12):1248-1254. DOI: 10.13288/j.11-2166/r.2023.12.011.
目的
2
观察通络利胆汤治疗低γ-谷氨酰转肽酶(GGT)型婴儿胆汁淤积性肝病的临床疗效。
方法
2
纳入2019年6月1日至2022年10月31日于北京儿童医院中医科门诊及病房的低GGT型婴儿胆汁淤积性肝病且符合肝络瘀滞、湿热内蕴证患儿144例,按随机对照表分为治疗组和对照组各72例。对照组给予口服熊去氧胆酸胶囊、葡醛内酯片及补充脂溶性维生素治疗,治疗组在对照组基础上口服中药通络利胆汤治疗。两组疗程均为12周。比较两组治疗12周胆汁淤积缓解率。比较两组患儿治疗2、4、8、12周中医病证疗效、肝功能[包括总胆红素(TBIL)、直接胆红素(DBIL)、GGT、总胆汁酸(TBA)、碱性磷酸酶(ALP)、谷氨酸氨基转移酶(ALT)、门冬氨酸氨基酸转移酶(AST)]恢复情况及治疗4、12周血透明质酸(HA)变化。随访6个月,比较两组患儿肝硬化失代偿发生率。
结果
2
最终治疗组67例,对照组62例完成观察,15例脱落病例采用意向性分析。治疗后治疗组胆汁淤积缓解率为31.94%(23/72),显著高于对照组的15.28%(11/72,
P
<0.05)。中医病证疗效方面,治疗组总有效率79.17%(57/72),显著高于对照组的59.72%(43/72,
P
<0.05)。治疗4、8、12周治疗组TBIL、DBIL、AST、ALT水平均较治疗前显著下降(
P
<0.05或
P
<0.01),治疗12周ALP水平较治疗前下降(
P
<0.01)。对照组治疗8、12周TBIL、ALT、ALP水平较治疗前下降(
P
<0.05或
P
<0.01);治疗4、8、12周DBIL、AST水平较治疗前下降(
P
<0.05或
P
<0.01),治疗2、8周TBA水平较治疗前上升(
P
<0.01)。治疗组治疗12周HA水平较治疗前下降(
P
<0.05),对照组治疗12周HA水平较治疗前上升(
P
<0.05)。治疗后两组间比较,治疗4、12周治疗组TBIL水平显著低于对照组(
P
<0.05);治疗4、8、12周治疗组DBIL水平低于对照组(
P
<0.05);治疗4、8周对照组AST水平显著低于治疗组(
P
<0.05或
P
<0.01);治疗4周治疗组ALT水平显著低于对照组(
P
<0.05);治疗8周对照组ALP水平显著低于治疗组(
P
<0.01),治疗12周治疗组显著低于对照组(
P
<0.05);治疗组治疗4、8周TBA水平显著低于对照组(
P
<0.05或
P
<0.01),治疗12周对照组低于治疗组(
P
<0.05);治疗组治疗12周HA水平较对照组显著下降(
P
<0.01)。治疗组55例、对照组42例随访6个月,治疗组发生肝硬化失代偿2例,对照组1例,两组比较差异无统计学意义(
P
>0.05)。
结论
2
通络利胆汤干预低GGT型婴儿胆汁淤积性肝病可有效改善胆汁淤积,缓解患儿临床症状,减缓肝纤维化进程。
Objective
2
To investigate the clinical effect of
Tongluo Lidan Decoction
(通络利胆汤) in the treatment of low γ-glutamyl transpeptidase (GGT) type of infantile cholestatic liver disease (CLD).
Methods
2
A total of 144 low GGT type of CLD infants who were admitted to the outpatient clinic and ward of the department of traditional Chinese medicine of Beijing Children's Hospital from June 1st, 2019 to October 31st, 2022 and were diagnosed as liver collaterals stagnation and internal damp-heat accumulation syndromes were included, and they were divided into 72 cases each in the treatment and control groups according to the random number table. The control group was treated with oral ursodeoxycholic acid capsules, glucuronide tablets and fat-soluble vitamins, while the treatment group was additionally given oral Chinese medicine
Tongluo Lidan Formula
(通络利胆方), both for 12 weeks. The remission rate of cholestasis after 12-week treatment was assessed and compared between groups. Effect regarding the traditional Chinese medicine (TCM) syndromes after 2-, 4-, 8- and 12-week treatment were assessed, as well as the recovery of liver function indicators including total bilirubin (TBIL), direct bilirubin (DBIL), GGT, total bile acid (TBA), alkaline phosphatase (ALP), glutamate aminotransferase (ALT), and aspartate aminotransferase (AST). The changes in blood hyaluronic acid (HA) after 4- and 12-week treatment were compared between groups. The incidence of liver cirrhosis decompensation was compared after 6-month follow up.
Results
2
Finally, 67 cases in the treatment group and 62 cases in the control group completed the trial, and intention-to-treat (ITT) analysis was used for the 15 drop-outs. After treatment, the remission rate of cholestasis was higher in the treatment group (23/72, 31.94%) than in the control group (11/72, 15.28%,
P
<0.05). For the effect regarding the TCM syndromes, the total effective rate was higher in the treatment group(57/72,79.17%) than in the control group (43/72, 59.72%,
P
<0.05). In the treatment group, the levels of TBIL, DBIL, AST and ALT decreased after 4-, 8- and 12-week treatment (
P
<0.05 or
P
<0.01), and the ALP level decreased after 12-week treatment (
P
<0.01). In the control group, the TBIL, ALT, and ALP levels decreased after 8- and 12-week treatment (
P
<0.05 or
P
<0.01), and DBIL and AST levels decreased after 4-, 8- and 12-week treatment (
P
<0.05 or
P
<0.01), while TBA level increased after 2- and 8-week treatment (
P
<0.05). Compared between groups, there were lower TBIL level after 4- and 12-week treatment (
P
<0.05) and lower DBIL level after 4-, 8- and 12-week treatment (
P
<0.05) in the treatment group than in the control group; the treatment group had higher AST level after 4- and 8-week treatment (
P
<0.05 or
P
<0.01) and lower ALT level after 4-week treatment (
P
<0.05) than the control group. The ALP level in the control group was significantly lower than that in the treatment group after 8-week treatment (
P
<0.01), while it was higher in the control group after 12-week treatment (
P
<0.05). The TBA level was significantly lower in the treatment group than in the control group after 4- and 8-week treatment (
P
<0.05 or
P
<0.01), while it was lower in the control group than in the treatment group after 12-week treatment (
P
<0.05). The HA level in the treatment group decreased after 12-week treatment (
P
<0.01). Fifty-five cases in the treatment group and 42 cases in the control group were followed up for 6 months; two cases of liver cirrhosis decompensation occurred in the treatment group as well as one case in the control group with no significant difference (
P
>0.05)).
Conclusion
2
Tongluo Lidan Decoction
in treatment of low γ-GT type of infantile CLD can effectively improve cholestasis, relieve clinical symptoms, slow down the process of liver fibrosis and promote remission.
FAWAZ R , BAUMANN U , EKONG U , et al . Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the north American society for pediatric gastroenterology, hepatology, and nutrition and the European society for pediatric gastroenterology, hepatology, and nutrition [J]. J Pediatr Gastroenterol Nutr , 2017 , 64 ( 1 ): 154 - 168 .
王建设 , 库尔班江·阿布都西库尔 , 李丽婷 . 婴儿胆汁淤积性肝病基因诊断 [J]. 中国实用儿科杂志 , 2013 , 28 ( 4 ): 254 - 257 .
LU FT , WU JF , HSU HY , et al . γ-Glutamyl transpeptidase level as a screening marker among diverse etiologies of infantile intrahepatic cholestasis [J]. J Pediatr Gastroenterol Nutr , 2014 , 59 ( 6 ): 695 - 701 .
舒静 , 何强 , 穆静 , 等 . 基于肝络病理论治疗婴儿肝内胆汁淤积性肝病 [J]. 中医杂志 , 2021 , 63 ( 1 ): 79 - 81 .
MOYER V , FREESE DK , WHITINGTON PF , et al . Guideline for the evaluation of cholestatic jaundice in infants:recommendations of the north American society for pediatric gastroenterology, hepatology and nutrition [J]. J Pediatr Gastroenterol Nutr , 2004 , 39 ( 2 ): 115 - 128 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 181 - 182 .
顾敏勇 , 杨燕 , 孙彦丽 , 等 . 中医儿科临床诊疗指南·胎黄(修订) [J]. 中医儿科杂志 , 2018 , 14 ( 2 ): 5 - 9 .
吴以岭 . 络病学 [M]. 北京 : 中国中医药出版社 , 2017 : 2 .
万霞 , 李赞华 , 刘建平 . 临床研究中的样本量估算:(1)临床试验 [J]. 中医杂志 , 2007 , 48 ( 6 ): 504 - 507 .
中华医学会肝病学分会 , 中华医学会消化病学分会 , 中华医学会感染病学分会 . 胆汁淤积性肝病诊断和治疗共识(2015) [J]. 实用肝脏病杂志 , 2016 , 19 ( 6 ): 2 - 12 .
中华医学会肝病学分会 . 肝硬化诊治指南 [J]. 现代医药卫生 , 2020 , 36 ( 2 ): 320, 插 1 -插18.
国家中医药管理局医政司 . 中医儿科病证诊断疗效标准 [S]. 南京 : 南京大学出版社 , 1994 : 86 .
朱启瑢 , 王建设 . 婴儿胆汁淤积症的鉴别诊断思路 [J]. 临床肝胆病杂志 , 2011 , 27 ( 7 ): 679 - 693 .
陆伦根 , 蔡晓波 , 王建设 , 等 . 胆汁淤积性肝病管理指南(2021) [J]. 临床肝胆病杂志 , 2022 , 38 ( 1 ): 62 - 69 .
CABRERA-ABREU JC , GREEN A . Gamma-glutamyltransferase: value of its measurement in paediatrics [J]. Ann Clin Biochem , 2002 , 39 ( Pt 1 ): 22 - 25 .
FANG LJ , WANG XH , KNISELY AS , et al . Chinese children with chronic intrahepatic cholestasis and high γ-glutamyl transpeptidase: clinical features and association with ABCB4 mutations [J]. J Pediatr Gastroenterol Nutr , 2012 , 55 ( 2 ): 150 - 156 .
沈越利 , 崔怀中 , 荀运浩 . 全外显子组测序在成人不明原因肝病诊断中的价值 [J]. 中西医结合肝病杂志 , 2022 , 32 ( 2 ): 169 - 173 .
司远 , 车念聪 , 杜宇琼 , 等 . 浅析“肝络病”概念与特点 [J]. 环球中医药 , 2016 , 9 ( 2 ): 214 - 216 .
何强 , 尤圣杰 , 舒静 , 等 . 基于肝络病理论治疗儿童胆管消失综合征 [J]. 中华中医药杂志 , 2020 , 61 ( 4 ): 1853 - 1856 .
幺远 , 胡艳 , 柳静 , 等 . 裴学义儿科临证用药特色 [J]. 中华中医药杂志 , 2010 , 25 ( 12 ): 2016 - 2018 .
CAI Y , ZHENG Q , SUN R , et al . Recent progress in the study of Artemisiae Scopariae Herba (Yin Chen), a promising medicinal herb for liver diseases [J]. Biomed Pharmacother , 2020 , 130 : 110513 . doi: 10.1016/j.biopha.2020.110513 http://dx.doi.org/10.1016/j.biopha.2020.110513 .
尹爱武 , 高鹏飞 . 丹参在肝脏疾病防治中的应用及作用机制研究进展 [J]. 天然产物研究与开发 , 2021 , 33 ( 6 ): 1057 - 1062 .
潘维 , 周卓 . 金钱草药用价值及研究 [J]. 中国民族民间医药 , 2010 , 19 ( 9 ): 11 - 12 .
任强 , 王红玲 , 周学刚 , 等 . 泽兰的化学成分、质量分析及药理作用研究进展 [J]. 中国药房 , 2015 , 26 ( 18 ): 2588 - 2592 .
吴玲芳 , 王子墨 , 赫柯芊 , 等 . 赤芍的化学成分和药理作用研究概况 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 18 ): 198 - 206 .
张妍妍 , 韦建华 , 卢澄生 , 等 . 桃仁化学成分、药理作用及质量标志物的预测分析 [J]. 中华中医药学刊 , 2022 , 40 ( 1 ): 234 - 241 .
乌吉木 , 吉日木巴图 , 王蕊 . 基于分子对接技术的红花抗胆汁淤积作用机制的研究 [J]. 时珍国医国药 , 2019 , 30 ( 4 ): 842 - 844 .
WU S , YUE Y , TIAN H , et al . Carthamus red from Carthamus tinctorius L. exerts antioxidant and hepatoprotective effect against CCl 4 -induced liver damage in rats via the Nrf2 pathway [J]. J Ethnopharmacol , 2013 , 148 ( 2 ): 570 - 578 .
FEVERY J . Bilirubin in clinical practice: a review [J]. Liver Int , 2008 , 28 ( 5 ): 592 - 605 .
宋国培 . 正确判定肝功能检查的临床意义 [J]. 中国实验诊断学 , 1997 , 1 ( 2 ): 11 - 14 .
KRONES E , ERWA W , TRAUNER M , et al . Serum alkaline phosphatase levels accurately reflect cholestasis in mice [J]. Hepatology , 2015 , 62 ( 3 ): 981 - 983 .
李慧萍 , 郑雪琴 , 赵群 , 等 . Ⅲ型前胶原、Ⅳ型胶原、层黏连蛋白和透明质酸酶在诊断肝纤维化程度中的应用 [J]. 检验医学与临床 , 2019 , 16 ( 5 ): 666 - 668 .
0
浏览量
2
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号